Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1NET 1Endocrine 1

Conditions

Pituitary Neoplasms 1Neuroendocrine Tumors 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Critical Pathways × Endocrine × Clear all
NCT06015802 2023-08-29

Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors

Sun Yat-sen University

Recruiting
300 enrolled
EndocrineNET

Pituitary Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡